AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protalix BioTherapeutics, Inc. Director's Dealing 2021

Feb 16, 2021

33807_dirs_2021-02-16_8d64a111-6f89-4829-bb88-6e8cc2dda370.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2021-02-12

Reporting Person: Dexcel Pharma Technologies Ltd. (10% Owner)
Reporting Person: Oren Dan (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4556031	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock Purchase Warrants	$2.36	2025-03-11	Common Stock (2816901)		Direct

Footnotes

F1: The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more the 9.99% of the Issuer's outstanding common shares by the warrantholder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not exercisable.